Strensiq Asfotase Alfa Application Scope

Strensiq (Asfotase Alfa) is a recombinant human alkaline phosphatase enzyme replacement therapy indicatedhypophosphatasia (HPP), a rare genetic disorder that affects bone mineralization.

HPP leads to defective or insufficient levels of the alkaline phosphatase enzyme, resulting in **bone defobone deformities, fractures, muscle weakness, and, in severe cases, premature death.

Strensiq is designed to replace the deficient enzyme and improve bone health in patients with childhood-onset and adult-onset HPP.

Strensiq Asfotase Alfa Characteristics

Ingredients:
- Active ingredient: Asfotase Alfa (recombinant human tissue non-specific alkaline phosphatase)
- Excipients: Includes stabilizers, buffers, and other inactive ingredi
Properties:Asfotase Alfa is a recombinant enzyme that mimics the natural alkaline phosphatase enzyme, which is crucial for bone mineralization and the proper functioning of various organs. By replacing the missing enzyme in paStrensiq helps improve bone health, muscle strength, and reduces the risk of fractures.
Specification:
- Formulation: Available as an injectable solution for subcutaneous use.
- Strength: Available in 6 mg/mL vials for injection.
Storage:
- Store in a refrigerator at 2°C to 8°C. Do not freeze.
- Protect from light.
Expiry Date:Typically 24 months from the manufacturing date (check the specific batch for the exact expiry).
Executive Standard:Meets FDA or other regulatory authority standards for biologics.
Approval Number:Specific approval number from the FDA or other relevant reg
Manufacturer:Alexion Pharmaceuticals or other authorized manufacturers.

Guidelines For The Use Of Strensiq Asfotase Alfa

Dosage and Administration:

Initial dose: The typical starting dose is 6 mg/kg body weight, administered subcutaneously once a week.
Depending on the patient’s response, the dose and frequency may be adjusted.
It is important to follow physician guidance on dosing to achieve the best clinical outcomes.

Adverse Reactions:

Common side effects include injection site reactions (such as redness or swelling), headache, fever, and nausea.
Serious side effects may include hypersensitivity reactions (e.g., anaphylaxis), bone pain, and gastrointestinal symptoms.

Medication Limitations

Contraindications:

Hypersensitivity to **AsAsfotase Alfa or any of its components.
Contraindicated in patients with severe renal impairment or end-stage kidney disease.

Precautions:

Monitor for potential allergic reactions, particularly after the fir
Regular monitoring of calcium levels is recommended to avoid complications.

Strensiq Asfotase Alfa Interactions

Drug Interactions:No significant drug-drug interactions have been identified. However, caution should be exerciStrensiq in combination with other **bone-modifying abone-modifying agents or treatments that may affect mineral metabolism.

Note:

If there is a new packaging for the drug, the new packaging shall prevail. The above information is sourced from HongKong DengYue Medicine. It is only for internal discussion among medical staff and does not serve as a basis for medication. For specific medication guidelines, please consult the attending physician.